Company intelligence / Profile preview

Hubble Therapeutics

Hanover, New Hampshire, United Stateshubbletx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Hubble Therapeutics is developing HUB-101, a gene therapy targeting LCA16 and SVD, two rare eye disorders caused by mutations in the KCNJ13 gene. The company recently secured funding to advance to human clinical trials and has partnered with Andelyn Biosciences for manufacturing.[2][3][4]

Therapeutic areas: Ophthalmology
Modalities: Gene therapy
Industry: Biotech

Drug pipeline

1 asset

HUB-101

Preclinical

Partnerships

Andelyn Biosciences

Beyond the preview

Go deeper on Hubble Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hubble Therapeutics.

Explore the full profile